Cost analysis of drug treatment in hypertensive patients at social security health care family medicine units

• Main Authors: Juan Figueroa-García (Author), Víctor Granados-García (Author), Ernesto Roldán-Valadez (Author), David Rojano-Mejía (Author), Jairo Enoc Cruz-Toledo (Author), Silvia Palomo-Piñón (Author)
• Format: Book
• Published: Instituto Nacional de Salud Pública, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 0036-3634; 10.21149/12972
• Keywords: hypertension; cost allocation; drug therapy; Public aspects of medicine; RA1-1270
• Source: Salud Pública de México, Vol 64, Iss 2, Pp 188-195 (2022)

Objective. To estimate the increase of drug treatment costs associated with predictive factors of hypertensive patients in family medicine units. Materials and methods. A generalized linear model was employed to estimate costs with data from a microcosting costing study for a 1-year time horizon. Sources of dada were medical electronic files, phar­macy records and unitary prices updated to 2019. Results. From a total of 864 patients older than 65 years were 67% and women 65%. Factors with most influence on mean drug treatment costs were diabetes, age and complications associ­ated with hypertension. Mean annual cost of antihypertensive treatment was 61 dollars (CI95% 55,67) and median were 32 dollars (IQR 30,35) per patient. Incremental costs for diabetes were 23 dollars (CI95% 13,33) and 25 dollars (CI95% 5, 45) in the group of ≥ 65 years. Conclusion. Diabetes, age and complications were the factors with largest influence on hypertension pharmacological costs.